| EER | ENST | ENSG | GeneName | Region | Repeat | dsRNA structure | | chr16:84427453-84427635:+ | ENST00000420010.5 | ENSG00000064270.11 | ATP2C2 | ncRNA_intronic | AluSx1 | chr16:84427453-84427635:+.alignment |
| chr16:84427453-84427635:+ | ENST00000565631.4 | ENSG00000064270.11 | ATP2C2 | ncRNA_intronic | AluSx1 | chr16:84427453-84427635:+.alignment |
| chr16:84429133-84431502:+ | ENST00000420010.5 | ENSG00000064270.11 | ATP2C2 | ncRNA_intronic | MLT1C,L2c,L2b,MIRb,L2,AluSz,AluSq2 | chr16:84429133-84431502:+.alignment |
| chr16:84429133-84431502:+ | ENST00000565631.4 | ENSG00000064270.11 | ATP2C2 | ncRNA_intronic | MLT1C,L2c,L2b,MIRb,L2,AluSz,AluSq2 | chr16:84429133-84431502:+.alignment |
| chr16:84432601-84433646:+ | ENST00000420010.5 | ENSG00000064270.11 | ATP2C2 | ncRNA_intronic | MER5A1,AluSx1,AluSg,AluJb | chr16:84432601-84433646:+.alignment |
| chr16:84432601-84433646:+ | ENST00000565631.4 | ENSG00000064270.11 | ATP2C2 | ncRNA_intronic | MER5A1,AluSx1,AluSg,AluJb | chr16:84432601-84433646:+.alignment |
| chr16:84434730-84437826:+ | ENST00000420010.5 | ENSG00000064270.11 | ATP2C2 | ncRNA_intronic | AluSp,MER104,L1MB7,MER102a,AluSz,AluSx,AluJb | chr16:84434730-84437826:+.alignment |
| chr16:84434730-84437826:+ | ENST00000565631.4 | ENSG00000064270.11 | ATP2C2 | ncRNA_intronic | AluSp,MER104,L1MB7,MER102a,AluSz,AluSx,AluJb | chr16:84434730-84437826:+.alignment |
| chr16:84449606-84450798:+ | ENST00000420010.5 | ENSG00000064270.11 | ATP2C2 | ncRNA_intronic | NoRepeat | chr16:84449606-84450798:+.alignment |
| chr16:84449606-84450798:+ | ENST00000565631.4 | ENSG00000064270.11 | ATP2C2 | ncRNA_intronic | NoRepeat | chr16:84449606-84450798:+.alignment |
| ID_events | cancer | TypeID | ImmuneCell | P | R | CorrelationPlot |
| chr16:84429133-84431502:+ | BRCA | EER | T_cells_CD4_memory_activated | 8.3848e-03 | 0.3653 |  |
| ENSG00000064270.11,ATP2C2 | BRCA | EAG | Neutrophils | 4.8111e-02 | 0.2541 |  |
| ENSG00000064270.11,ATP2C2 | CESC | EAG | Dendritic_cells_activated | 3.8323e-02 | 0.4166 |  |
| chr16:84432601-84433646:+ | COAD | EER | B_cells_memory | 2.0749e-02 | 0.5129 |  |
| ENSG00000064270.11,ATP2C2 | COAD | EAG | B_cells_memory | 3.7051e-02 | 0.2110 |  |
| chr16:84429133-84431502:+ | ESCA | EER | T_cells_CD4_naive | 4.4788e-03 | 0.4252 |  |
| chr16:84432601-84433646:+ | ESCA | EER | Mast_cells_activated | 8.0233e-04 | -0.5968 |  |
| chr16:84434730-84437826:+ | ESCA | EER | Neutrophils | 5.9121e-03 | 0.4985 |  |
| chr16:84429133-84431502:+ | LUAD | EER | NK_cells_activated | 2.8843e-02 | -0.2872 |  |
| ENSG00000064270.11,ATP2C2 | LUAD | EAG | T_cells_CD4_memory_resting | 4.9096e-02 | -0.2361 |  |
| chr16:84429133-84431502:+ | PRAD | EER | T_cells_CD8 | 4.9599e-02 | 0.4050 |  |
| ENSG00000064270.11,ATP2C2 | READ | EAG | Macrophages_M1 | 4.6876e-02 | 0.3084 |  |
| chr16:84429133-84431502:+ | STAD | EER | Neutrophils | 9.5916e-03 | 0.2795 |  |
| chr16:84432601-84433646:+ | STAD | EER | Neutrophils | 1.3531e-02 | 0.2982 |  |
| chr16:84434730-84437826:+ | STAD | EER | T_cells_follicular_helper | 3.5572e-02 | 0.2719 |  |
| chr16:84449606-84450798:+ | STAD | EER | B_cells_naive | 1.6308e-02 | 0.3562 |  |
| ID_events | cancer | HallmarkType | Type | P | R | CorrelationPlot |
| ENSG00000064270.11,ATP2C2 | BRCA | GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE | EAG | 1.0354e-03 | 0.4099 |  |
| chr16:84429133-84431502:+ | BRCA | GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE | EER | 2.8105e-03 | 0.4100 |  |
| chr16:84429133-84431502:+ | CESC | GSVA_HALLMARK_MYC_TARGETS_V2 | EER | 1.7973e-03 | 0.6268 |  |
| ENSG00000064270.11,ATP2C2 | CESC | GSVA_HALLMARK_PROTEIN_SECRETION | EAG | 1.8917e-02 | -0.4659 |  |
| chr16:84432601-84433646:+ | COAD | GSVA_HALLMARK_HEDGEHOG_SIGNALING | EER | 3.8752e-02 | 0.4652 |  |
| chr16:84429133-84431502:+ | COAD | GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY | EER | 1.5969e-03 | 0.3280 |  |
| chr16:84449606-84450798:+ | ESCA | GSVA_HALLMARK_PANCREAS_BETA_CELLS | EER | 2.3278e-02 | 0.4131 |  |
| chr16:84432601-84433646:+ | ESCA | GSVA_HALLMARK_MITOTIC_SPINDLE | EER | 4.8357e-02 | 0.3764 |  |
| chr16:84434730-84437826:+ | ESCA | GSVA_HALLMARK_P53_PATHWAY | EER | 3.5340e-03 | 0.5239 |  |
| ENSG00000064270.11,ATP2C2 | LUAD | GSVA_HALLMARK_DNA_REPAIR | EAG | 4.8304e-02 | 0.2369 |  |
| ENSG00000064270.11,ATP2C2 | PRAD | GSVA_HALLMARK_PEROXISOME | EAG | 8.1802e-04 | 0.5960 |  |
| chr16:84429133-84431502:+ | PRAD | GSVA_HALLMARK_PEROXISOME | EER | 4.5199e-03 | 0.5590 |  |
| ENSG00000064270.11,ATP2C2 | READ | GSVA_HALLMARK_UV_RESPONSE_UP | EAG | 2.7003e-02 | 0.3412 |  |
| chr16:84429133-84431502:+ | STAD | GSVA_HALLMARK_GLYCOLYSIS | EER | 6.0561e-04 | 0.3644 |  |
| ID_events | cancer | Drug | Type | P | R | CorrelationPlot |
| ENSG00000064270.11,ATP2C2 | BRCA | Docetaxel | EAG | 3.7377e-02 | -0.2672 |  |
| chr16:84429133-84431502:+ | BRCA | CCT007093 | EER | 1.5481e-02 | 0.3374 |  |
| chr16:84429133-84431502:+ | CESC | Cytarabine | EER | 3.3946e-03 | -0.5964 |  |
| ENSG00000064270.11,ATP2C2 | CESC | AZD6482 | EAG | 1.5485e-05 | 0.7506 |  |
| chr16:84432601-84433646:+ | COAD | GDC.0449 | EER | 2.9332e-02 | -0.4872 |  |
| ENSG00000064270.11,ATP2C2 | COAD | JNK.Inhibitor.VIII | EAG | 3.7388e-03 | 0.2903 |  |
| chr16:84429133-84431502:+ | COAD | JNK.Inhibitor.VIII | EER | 3.4124e-04 | 0.3693 |  |
| chr16:84429133-84431502:+ | ESCA | ABT.888 | EER | 1.8217e-02 | 0.3586 |  |
| chr16:84449606-84450798:+ | ESCA | AZD6482 | EER | 2.8938e-02 | 0.3990 |  |
| chr16:84432601-84433646:+ | ESCA | CMK | EER | 2.6761e-03 | 0.5456 |  |
| chr16:84434730-84437826:+ | ESCA | Gefitinib | EER | 3.6398e-07 | -0.7891 |  |
| ENSG00000064270.11,ATP2C2 | ESCA | CGP.60474 | EAG | 7.5845e-03 | -0.3443 |  |
| ENSG00000064270.11,ATP2C2 | LUAD | JNK.Inhibitor.VIII | EAG | 4.9463e-02 | -0.2357 |  |
| ENSG00000064270.11,ATP2C2 | PRAD | CHIR.99021 | EAG | 3.2292e-03 | 0.5368 |  |
| chr16:84429133-84431502:+ | PRAD | Epothilone.B | EER | 1.2775e-02 | -0.5003 |  |
| chr16:84434730-84437826:+ | STAD | BMS.708163 | EER | 4.6878e-02 | -0.2576 |  |
| ENSG00000064270.11,ATP2C2 | STAD | Metformin | EAG | 2.7717e-02 | 0.2027 |  |